Journal
CANCERS
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers12061453
Keywords
lncRNA; breast cancer; alternative splicing; estrogen receptor; RNA-Seq
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro [IG 15600]
- Fondazione CRT [2017.0823]
- University of Torino
Ask authors/readers for more resources
DSCAM-AS1is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ER alpha).DSCAM-AS1expression is analyzed in 30 public datasets and, additionally, by qRT-PCR in tumors from 93 BC patients, to uncover correlations with clinical data. Moreover, the effect of DSCAM-AS1 knockdown on gene expression and alternative splicing is studied by RNA-Seq in MCF-7 cells. We confirmDSCAM-AS1overexpression in high grade Luminal A, B, and HER2+ BCs and find a significant correlation with disease relapse. In total, 908 genes are regulated byDSCAM-AS1-silencing, primarily involved in the cell cycle and inflammatory response. Noteworthily, the analysis of alternative splicing and isoform regulation reveals 2085 splicing events regulated byDSCAM-AS1, enriched in alternative polyadenylation sites, 3 ' UTR (untranslated region) shortening and exon skipping events. Finally, theDSCAM-AS1-interacting splicing factor heterogeneous nuclear ribonucleoprotein L (hnRNPL) is predicted as the most enriched RBP for exon skipping and 3 ' UTR events. The relevance ofDSCAM-AS1overexpression in BC is confirmed by clinical data and further enhanced by its possible involvement in the regulation of RNA processing, which is emerging as one of the most important dysfunctions in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available